This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-07-28 and is reviewed periodically as new material appears.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
=== Pharmacodynamics === 2C-T-36 has a Ki of 0.35 nM at the serotonin 5-HT2A receptor, and an EC50Tooltip half-maximal effective concentration of 4.1 nM at the serotonin 5-HT2A receptor and 7.3 nM at the serotonin 5-HT2C receptor, compared to 88 nM at the serotonin 5-HT2B receptor. It is a potent, selective, long acting, and orally active agonist for the serotonin 5-HT2A and 5-HT2C receptors and produces psychedelic-like responding in several different animal species. The interactions of 2C-T-36 with numerous other receptors and targets have also been described.
Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis. It is a cyclic peptide that functions as a selective interleukin 23 (IL-23) receptor antagonist. It is a synthetic peptide that binds selectively to the IL-23 receptor (IL-23R) with high affinity and competitively antagonizes the binding of IL-23. It is an immunosuppressant and interleukin inhibitor. It is being developed by Johnson & Johnson. Icotrokinra was approved for medical use in the United States in March 2026.
Just behind Piazza Castello stands the Turin Cathedral, dedicated to Saint John the Baptist, which is the major church of the city. It was built during 1491–1498 and is adjacent to an earlier bell tower (1470). Annexed to the cathedral is the Chapel of the Holy Shroud, the current resting place of the Shroud of Turin. The chapel was added to the structure in 1668–1694, designed by Guarini. The Basilica of Corpus Domini was built to celebrate an alleged miracle which took place during the sack of the city in 1453, when a soldier was carrying off a monstrance containing the Blessed Sacrament; the monstrance fell to the ground, while the host remained suspended in air. The present church, erected in 1610 to replace the original chapel which stood on the spot, is the work of Ascanio Vitozzi.
Sources: en.wikipedia.org
GTP = 3′,5′-cyclic GMP + diphosphate It is often part of the G protein signaling cascade that is activated by low intracellular calcium levels and inhibited by high intracellular calcium levels. In response to calcium levels, guanylate cyclase synthesizes cGMP from GTP. cGMP keeps cGMP-gated channels open, allowing for the entry of calcium into the cell. Like cAMP, cGMP is an important second messenger that internalizes the message carried by intercellular messengers such as peptide hormones and nitric oxide and can also function as an autocrine signal. Depending on cell type, it can drive adaptive/developmental changes requiring protein synthesis. In smooth muscle, cGMP is the signal for relaxation, and is coupled to many homeostatic mechanisms including regulation of vasodilation, vocal tone, insulin secretion, and peristalsis. Once formed, cGMP can be degraded by phosphodiesterases, which themselves are under different forms of regulation, depending on the tissue.
A power supply issue at Thames Water's west London treatment works leaves thousands of properties in south west London without water or with low water pressure. 14 September – Health Secretary Steve Barclay gives his backing to the introduction of Martha's Rule to hospitals in England, where patients are made aware that they are entitled to a second opinion. NHS England will also begin implementing the rule. The Metropolitan Police have paid damages to two women who were arrested at a vigil for Sarah Everard, who was murdered by a serving police officer in March 2021. 15 September – Three people appear in court charged with the murder of Sara Sharif, and are remanded in custody. The Metropolitan Police apologises and agrees to pay compensation to Alfie Meadows, who sustained brain injuries after being hit with a baton by a police officer during the 2010 student protests. 16 September – A man is arrested in the Royal Mews near Buckingham Palace following reports of someone climbing a wall in the area; he is detained under the Serious Organised Crime and Police Act on suspicion of trespassing. 17 September – Heavy rain causes flash flooding in Kenton, Devon. 19 September – The UK government announces that commissioners will be appointed to oversee the running of Birmingham City Council following its recent financial troubles. 21 September – During a hearing at the Old Bailey, Daniel Khalife pleads not guilty to escaping from Wandsworth Prison. 22 September – Surrey Police release new pictures of Sara Sharif as they appeal for more information about her.
== Use as a lipid biomarker == Tetrahymanol has been found in many marine ciliates at relatively high concentrations, suggesting it may be a useful biomarker in the Earth's rock record. During diagenesis, the alcohol functional group is lost and tetrahymanol becomes gammacerane. Like other saturated triterpenoid skeletons, gammacerane is a highly stable molecule that can preserved in rocks on geological timescales. The oldest gammacerane biomarker was found in a rock 850 million years old. Based on microbial physiology studies, gammacerane was suggested as a potential biomarker for ocean stratification. When water columns stratify, anoxic conditions can form in the bottom waters. Ciliates living in these conditions must adapt to produce lipids that do not require molecular oxygen for their biosynthesis. A direct correlation between sterol availability and tetrahymanol synthesis in ciliates has been shown, leading to the hypothesis that gammacerane in sediments is a biomarker for ocean stratification. This hypothesis was later met with skepticism. While tetrahymanol had mostly been observed in ciliates, several bacteria were then shown to synthesize the lipid and many bacteria across multiple phyla had the gene for tetrahymanol synthase. This evidence has been used to question the potential of gammacerane as a biomarker for water column stratification. For instance, aerobic methanotrophic bacteria were shown to synthesize tetrahymanol. Thus it is not solely a response to anoxic environments.
Sources: en.wikipedia.org
== Constitutionality in the United States == In 2006, the Supreme Court ruled in Hill v. McDonough that death-row inmates in the United States could challenge the constitutionality of states' lethal injection procedures through a federal civil rights lawsuit. Since then, numerous death-row inmates have brought such challenges in the lower courts, claiming that lethal injection as practiced violates the ban on "cruel and unusual punishment" found in the Eighth Amendment to the United States Constitution. Lower courts evaluating these challenges have reached opposing conclusions. For example, courts have found that lethal injection as practiced in California, Florida, and Tennessee is unconstitutional. Other courts have found that lethal injection as practiced in Missouri, Arizona, and Oklahoma is constitutionally acceptable. As of 2014, California has nearly 750 prisoners condemned to death by lethal injection despite the moratorium imposed when, in 2006 a federal court found California's lethal injection procedures to be unconstitutional. A newer lethal injection facility has been constructed at San Quentin State Prison which cost over $800,000, but it has yet to be used because a state court found that the California Department of Corrections and Rehabilitation violated the California Administrative Procedure Act by attempting to prevent public oversight when new injection procedures were being created. On September 25, 2007, the United States Supreme Court agreed to hear a lethal-injection challenge arising from Kentucky, Baze v. Rees.
== Young adults == By far, the most common cause of severe hypoglycemia in this age range is insulin injected for type 1 diabetes. Circumstances should provide clues fairly quickly for the new diseases causing severe hypoglycemia. All of the congenital metabolic defects, congenital forms of hyperinsulinism, and congenital hypopituitarism are likely to have already been diagnosed or are unlikely to start causing new hypoglycemia at this age. Body mass is large enough to make starvation hypoglycemia and idiopathic ketotic hypoglycemia quite uncommon. Recurrent mild hypoglycemia may fit a reactive hypoglycemia pattern, but this is also the peak age for idiopathic postprandial syndrome, and recurrent "spells" in this age group can be traced to orthostatic hypotension or hyperventilation as often as demonstrable hypoglycemia.
2-carboxy-D-arabinitol + phosphate This enzyme belongs to the family of hydrolases, to be specific, those acting on phosphoric monoester bonds. The systematic name is 2-carboxy-D-arabinitol-1-phosphate 1-phosphohydrolase.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.